Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment
 |
NICHD Archive
Note: Information on this page was accurate at the time of publication.
This page is no longer being updated. |
September 4-6, 2018
Sponsor/Co-Sponsor(s)
Maternal and Pediatric Infectious Disease Branch (MPIDB), NICHD
National Institute of Allergy and Infectious Diseases
Location
Fishers Lane Conference Center, Room 1D13, 5601 Fishers Lane, Rockville, Maryland 20852
Purpose
Cytomegalovirus (CMV) causes significant health problems for infants who were infected in the womb and for people who become infected from organ or stem cell transplants. There is no licensed vaccine for CMV. Treatment of CMV infection is challenging because of the side effects of antiviral drugs and the emergence of drug-resistant strains. New approaches for both prevention and treatment will have a substantial public health impact.
Contact
Nahida Chakhtoura, NICHD
E-mail: nahida.chakhtoura@nih.gov
Please note: Views expressed during NICHD-sponsored events do not necessarily reflect the opinions or the official positions of NICHD, NIH, or HHS.
BACK TO TOP